Male Breast Cancer

Bernard-Marty, Chantal; Azambuja, Evandro de; Lago, Lissandra Dal; Piccart, Martine; Cardoso, Fátima

doi:10.1007/978-3-540-28266-2_42

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endocrine therapy (ET) with tamoxifen is the preferred adjuvant systemic therapy for ER + male BC, with demonstrated survival benefit [ 13 ]. The effectiveness of aromatase inhibitors (AIs) in this setting is less clear and this ET should not be prescribed without a gonadotropin-releasing hormone (GnRH) analogue [ 14 , 15 ]. Abemaciclib, the only approved cyclin dependent kinase 4/6 (CDK4/6) inhibitor in the adjuvant setting for ER + BC, has improved event-free survival in patients with high risk of recurrence, as per the landmark results of the MonarchE trial [ 16 ].…”

Section: Introductionmentioning

confidence: 99%